Compositions and methods for the treatment of gastrointestinal indications

Abstract

The present invention relates to identification of Oroxylum indicum, Indian medicinal plant as a rich source for flavanoid compounds. Mucoprotective and antigastric ulcer properties in the flavone class of compounds isolated therefrom have been identified along with a flavanoids mixture in substantial yields from hexane and acetone extracts. The hexane extract was fractionated, purified and the compounds identified as Oroxylin A, Chrysin and Baicalein. The acetone extract was purified and the compounds obtained identified as methoxy chrysin, Oroxyloside methyl ester and chrysin-7-O-methyl glycoside.

1 . Method for treatment of gastric ulcer comprising administering to a subject a pharmaceutically acceptable amount of a mucoprotective and antigastric ulcer agent selected the group consisting of OA-5 and analogues thereof, selected in turn from the group consisting of NMC-2, NMC-3, CHN-2, CHM-3, CPP-2, CG, and CGL. 
     
     
         2 .- 6 . (canceled) 
     
     
         7 . The method of  claim 1  wherein, OA-5 provides reduced glandular ulcer index up to 78.22% induced by cold stress restraint ulceration at dose level of 50 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         8 . The method of  claim 1  wherein, OA-5 provides reduced glandular ulcer index up to 75.45% induced by cold stress restraint ulceration at dose level of 25 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         9 . The method of  claim 1  wherein, OA-5 provides reduced glandular ulcer index up to 50.14% induced by cold stress restraint ulceration at dose level of 15 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         10 . The method of  claim 1  wherein, OA-5 provides reduced glandular ulcer index up to 41.92% induced by cold stress restraint ulceration at dose level of 10 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         11 . The method of  claim 1  wherein, OA-5 provides reduced glandular ulcer index up to 31.55% induced by cold stress restraint ulceration at dose level of 5 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         12 . The method of  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 85.00% induced by 50% ethanol ulceration at dose level of 50 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.51% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         13 . The method of  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 82.5% induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.51% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         14 . The method of  claim 1  wherein, 0A-5 provides marked gastric mucosal protection up to 60.61% induced by 50% ethanol ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.51% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         15 . The method of  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 35.00% induced by 50% ethanol ulceration at dose level of 10 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.51% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         16 . The method of  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 30.01% induced by 50% ethanol ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.51% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         17 . The method of  claim 1  wherein, OA-5 provides elevation pH up to 4.95 induced by 50% ethanol ulceration at dose level of 50 mg/kg of bodyweight comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         18 . The method of  claim 1  wherein, OA-5 provides elevation pH up to 6.81 induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         19 . The method of  claim 1  wherein, OA-5 provides elevation pH up to 4.5 induced by 50% ethanol ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         20 . The method of  claim 1  wherein, OA-5 provides elevation pH up to 4.66 induced by 50% ethanol ulceration at dose level of 10 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         21 . The method of  claim 1  wherein, OA-5 provides elevation pH up to 3.5 induced by 50% ethanol ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         22 . The method of  claim 1  wherein, OA-5 provides increase gastric juice secretion up to 7.4 ml induced by 50% ethanol ulceration at dose level of 50 mg/kg of bodyweight comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         23 . The method of  claim 1  wherein, OA-5 provides increase gastric juice secretion up to 5.5 ml induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         24 . The method of  claim 1  wherein, OA-5 provides increase gastric juice secretion up to 4.5 ml induced by 50% ethanol ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         25 . The method of  claim 1  wherein, OA-5 provides increase gastric juice secretion up to 4.2 ml induced by 50% ethanol ulceration at dose level of 10 mg/kg of bodyweight in comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         26 . The method of  claim 1  wherein, OA-5 provides increase gastric juice secretion up to 4.0 ml induced by 50% ethanol ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         27 . The method of  claim 1  wherein, OA-5 provides reduction in acidity level up to 18.25 m Eg induced by 50% ethanol ulceration at dose level of 50 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         28 . The method of  claim 1  wherein, OA-5 provides reduction in acidity level up to 12.4 m Eg induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         29 . The method of  claim 1  wherein, OA-5 provides reduction in acidity level up to 29.66 m Eg induced by 50% ethanol ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         30 . The method as claimed in  claim 1  wherein, OA-5 provides reduction in acidity level up to 31.33 m Eg induced by 50% ethanol ulceration at dose level of 10 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         31 . The method as claimed in  claim 1  wherein, OA-5 provides reduction in acidity level up to 42.66 m Eg induced by 50% ethanol ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         32 . The method as claimed in  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 79.85% induced by pylorus ligated ulceration at dose level of 50 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         33 . The method as claimed in  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 75.07% induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         34 . The method as claimed in  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 70.07% induced by pylorus ligated ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         35 . The method as claimed in  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 59.78% induced by pylorus ligated ulceration at dose level of 10mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         36 . The method as claimed in  claim 1  wherein, OA-5 provides marked gastric mucosal protection up to 46.80% induced by pylorus ligated ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         37 . The method as claimed in  claim 1  wherein, OA-5 provides elevation pH up to 4.62 induced by pylorus ligated ulceration at dose level of 50 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         38 . The method as claimed in  claim 1  wherein, OA-5 provides elevation pH up to 5.62 induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         39 . The method as claimed in  claim 1  wherein, 0A-5 provides elevation pH up to 4.35 induced by pylorus ligated ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         40 . The method as claimed in  claim 1  wherein, OA-5 provides elevation pH up to 3.58 induced by pylorus ligated ulceration at dose level of 10 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         41 . The method as claimed in  claim 1  wherein, OA-5 provides elevation pH up to 3.25 induced by pylorus ligated ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         42 . The method as claimed in  claim 1  wherein, OA-5 provides increase in gastric juice secretion up to 2.5 ml induced by pylorus ligated ulceration at dose level of 50 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         43 . The method as claimed in  claim 1  wherein, OA-5 provides increase in gastric juice secretion up to 2.1 ml induced by pylorus ligated ulceration at dose level of 50 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         44 . The method as claimed in  claim 1  wherein, OA-5 provides increase in gastric juice secretion up to 3.62 ml induced by pylorus ligated ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         45 . The method as claimed in  claim 1  wherein, OA-5 provides increase in gastric juice secretion up to 3.5 ml induced by pylorus ligated ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         46 . The method as claimed in  claim 1  wherein, OA-5 provides reduction in acidity level up to 32.66 m Eg induced by pylorus ligated ulceration at dose level of 50 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         47 . The method as claimed in  claim 1  wherein, OA-5 provides reduction in acidity level up to 30.18 m Eg induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         48 . The method as claimed in  claim 1  wherein, OA-5 provides reduction in acidity level up to 30.25 m Eg induced by pylorus ligated ulceration at dose level of 15 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         49 . The method as claimed in  claim 1  wherein, OA-5 provides reduction in acidity level up to 42.9 m Eg induced by pylorus ligated ulceration at dose level of 10 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         50 . The method as claimed in  claim 1  wherein, OA-5 provides reduction in acidity level up to 45.5 m Eg induced by pylorus ligated ulceration at dose level of 5 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         51 . The method as claimed in  claim 1  wherein, NMC-2 provides reduced glandular ulcer index up to 59.67% induced by cold stress restraint ulceration at dose level of 25 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         52 . The method as claimed in  claim 1  wherein, NMC-2 provides gastric mucosal protection up to 57.5% induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.51% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         53 . The method as claimed in  claim 1  wherein, NMC-2 provides elevation pH up to 4.75 induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         54 . The method as claimed in  claim 1  wherein, NMC-2 provides increase gastric juice secretion up to 4.8 ml induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         55 . The method as claimed in  claim 1  wherein, NMC-2 provides reduction in acidity level up to 30.8 m Eg induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         56 .- 59 . (canceled) 
     
     
         60 . The method as claimed in  claim 1  wherein, NMC-3 provides reduced glandular ulcer index up to 57.92% induced by cold stress restraint ulceration at dose level of 25 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         61 . The method as claimed in  claim 1  wherein, CHN-2 provides reduced glandular ulcer index up to 56.12% induced by cold stress restraint ulceration at dose level of 25 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         62 . The method as claimed in  claim 1  wherein, CHM-3 provides reduced glandular ulcer index up to 52.64% induced by cold stress restraint ulceration at dose level of 25 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         63 . The method as claimed in  claim 1  wherein, CPP-2 provides reduced glandular ulcer index up to 61.44% induced by cold stress restraint ulceration at dose level of 25 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         64 . The method as claimed in  claim 1  wherein, CHN-2 provides marked gastric mucosal protection up to 58.44% induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         65 . The method as claimed in  claim 1  wherein, CHN-2 provides elevation pH up to 4.25 induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         66 . The method as claimed in  claim 1  wherein, CHN-2 provides increase in gastric juice secretion up to 1.8 ml induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         67 . The method as claimed in  claim 1  wherein, CHN-2 provides reduction in acidity level up to 31.18 m Eg induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         68 . The method as claimed in  claim 1  wherein, CPP-2 provides marked gastric mucosal protection up to 68.47% induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         69 . The method as claimed in  claim 1  wherein, CPP-2 provides elevation pH up to 3.25 induced by pylorus ligated ulceration at dose level of 25 mg/kg of body weight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         70 . The method as claimed in  claim 1  wherein, CPP-2 provides increase in gastric juice secretion up to 2.6 ml induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         71 . The method as claimed in  claim 1  wherein, CPP-2 provides reduction in acidity level up to 29.06 m Eg induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         72 .- 73 . (canceled) 
     
     
         74 . The method as claimed in  claim 1  wherein, CGL provides reduced glandular ulcer index up to 50.22% induced by cold stress restraint ulceration at dose level of 25 mg/kg of bodyweight in comparison with the reference standard ranitidine up to 78.83% reduction of ulcer index at dose level of 50 mg/kg of bodyweight. 
     
     
         75 . The method as claimed in  claim 1  wherein, CG provides gastric mucosal protection up to 52.5% induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.51% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         76 . The method as claimed in  claim 1  wherein, CG provides elevation pH up to 5.9 induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         77 . The method as claimed in  claim 1  wherein, CG provides increase gastric juice secretion up to 5.9 ml induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         78 . The method as claimed in  claim 1  wherein, CG provides reduction in acidity level up to 41.33 m Eg induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         79 . The method as claimed in  claim 1  wherein, CGL provides gastric mucosal protection up to 62.5% induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 61.26% gastric mucosal protection at dose level of 50 mg/kg of bodyweight in comparison with the reference to standard omeprazole up to 67.5% gastric mucosal protection at dose level of 30 mg/kg of bodyweight and in comparison with the reference to standard sucralfate up to 87.5% gastric mucosal protection at dose level of 400 mg/kg of bodyweight. 
     
     
         80 . The method as claimed in  claim 1  wherein, CGL provides elevation pH up to 3.9 induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 4.96 pH elevation at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 4.65 pH elevation at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 pH elevation at dose level of 400 mg/kg of bodyweight. 
     
     
         81 . The method as claimed in  claim 1  wherein, CGL provides increase gastric juice secretion up to 4.6 ml induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 5.0 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight in comparison with the reference standard omeprazole up to 3.5 ml gastric juice secretion at dose level of 30 mg/kg of bodyweight and comparison with the reference standard sucralfate up to 4.00 ml gastric juice secretion at dose level of 400 mg/kg of bodyweight. 
     
     
         82 . The method as claimed in  claim 1  wherein, CGL provides reduction in acidity level up to 39 m Eg induced by 50% ethanol ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 26.74 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight, in comparison with the reference standard omeprazole up to 32.01 m Eg mean level of reduction in acidity at dose level of 30 mg/kg of bodyweight and in comparison with the reference standard sucralfate up to 52.00 m Eg mean level of reduction in acidity at dose level of 400 mg/kg of bodyweight. 
     
     
         83 . The method as claimed in  claim 1  wherein, CG provides marked gastric mucosal protection up to 50.25% induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         84 . The method as claimed in  claim 1  wherein, CG provides elevation pH up to 3.5 induced by pylorus ligated ulceration at dose level of 25 mg/kg of body weight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         85 . The method as claimed in  claim 1  wherein, CG provides increase in gastric juice secretion up to 1.5 ml induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         86 . The method as claimed in  claim 1  wherein, CG provides reduction in acidity level up to 44.33 m Eg induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         87 . The method as claimed in  claim 1  wherein, CGL provides marked gastric mucosal protection up to 60.17% induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference to the standard ranitidine up to 78.39% gastric mucosal protection at dose level of 50 mg/kg of bodyweight. 
     
     
         88 . The method as claimed in  claim 1  wherein, CGL provides elevation pH up to 3.08 induced by pylorus ligated ulceration at dose level of 25 mg/kg of body weight in comparison with reference standard ranitidine up to 4.75 pH elevation at dose level of 50 mg/kg of bodyweight. 
     
     
         89 . The method as claimed in  claim 1  wherein, CGL provides increase in gastric juice secretion up to 4.83 ml induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 1.82 ml gastric juice secretion at dose level of 50 mg/kg of bodyweight. 
     
     
         90 . The method as claimed in  claim 1  wherein, CGL provides reduction in acidity level up to 40 m Eg induced by pylorus ligated ulceration at dose level of 25 mg/kg of bodyweight in comparison with reference standard ranitidine up to 31.8 m Eg mean level of reduction in acidity at dose level of 50 mg/kg of bodyweight. 
     
     
         91 .- 96 . (canceled)